The development of psoriasis during treatment with dupilumab is rare but in some cases, the severity of symptoms may lead to discontinuation of dupilumab, depriving patients from this highly effective medication despite improvement of pruritus, skin lesions and quality of life. In Received: 15 ...
Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis Summary Poor adherence with therapy is a major cause of treatment failure in atopic dermatitis. Reasons given are multifactorial, and include fear of real ... PE Beattie,MS Lewisjones - 《Clinical & Experimental...
His asthma is mainly viral induced and although under treatment with omalizumab and inhaled fluticasone he still had 3 mild episode between Sep 2011-May 2012. He stopped fluticasone in July 2012 and since then he has no episode. He is also free of symptoms between episodes with normal spirometr...
Adult patients with moderate to severe atopic dermatitis (AD) had a 1-year and 1.5-year upadacitinib drug survival of 91.5% and 80.2%, respectively. Upadacitinib was effective in treating patients with moderate to severe atopic dermatitis (AD) after more than 1 year of continuous trea...
This article provides comprehensive recommendations for the systemic treatment of severe pediatric psoriasis based on evidence obtained from a systematic r
Atopic dermatitis (AD) is a pruritic, eczematous dermatosis, the symptoms of which fluctuate with remissions and relapses. Staphylococcus aureus has been suggested to contribute to the exacerbation of AD and specific IgE antibodies to S. aureus have been detected in a group of patients with AD....
The Eczema Area and Severity Index (EASI) was 8.1, Severity Scoring of Atopic Dermatitis (SCORAD) was 66.4,Dermatology Life Quality Index (DLQI) was 18,Pruritus Numerical Rating Scale (NRS) was 10, which showed a severe atopic dermatitis.We referred to the guidelines for the treatment of PN...
Meaning This study found a clinical benefit of Janus kinase inhibition in combination with TCS therapy, the mainstay treatment for AD. Abstract Importance Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced disease severity in moderate to severe atopic dermatitis (AD) ...
Armstrong A, Ameen A, Bagel J, et al. Real-world effectiveness of tralokinumab in adults with atopic dermatitis: Interim data on improvements in patients with head and neck atopic dermatitis after up to 9 months of treatment in the TRACE study. Presented at the European Academy of Dermatology...
Patient-reported outcome measures (PROMs) can be used to assess daily symptoms and understand the impact of severe asthma and the burden of its treatment [4]. PROMs show promise as being useful to support clinical decision-making [5]. However, asthma-related PROMs have mostly been evaluated ...